|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: HAUS6 |
Gene summary for HAUS6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | HAUS6 | Gene ID | 54801 |
| Gene name | HAUS augmin like complex subunit 6 | |
| Gene Alias | Dgt6 | |
| Cytomap | 9p22.1 | |
| Gene Type | protein-coding | GO ID | GO:0000226 | UniProtAcc | Q7Z4H7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54801 | HAUS6 | C04 | Human | Oral cavity | OSCC | 5.06e-04 | 3.45e-01 | 0.2633 |
| 54801 | HAUS6 | C21 | Human | Oral cavity | OSCC | 9.56e-04 | 2.05e-01 | 0.2678 |
| 54801 | HAUS6 | C30 | Human | Oral cavity | OSCC | 5.98e-17 | 7.90e-01 | 0.3055 |
| 54801 | HAUS6 | C38 | Human | Oral cavity | OSCC | 7.45e-04 | 5.17e-01 | 0.172 |
| 54801 | HAUS6 | C43 | Human | Oral cavity | OSCC | 6.16e-19 | 3.33e-01 | 0.1704 |
| 54801 | HAUS6 | C46 | Human | Oral cavity | OSCC | 1.82e-05 | 2.10e-01 | 0.1673 |
| 54801 | HAUS6 | C51 | Human | Oral cavity | OSCC | 5.91e-04 | 3.64e-01 | 0.2674 |
| 54801 | HAUS6 | SYSMH1 | Human | Oral cavity | OSCC | 1.22e-04 | 1.43e-01 | 0.1127 |
| 54801 | HAUS6 | SYSMH2 | Human | Oral cavity | OSCC | 1.96e-12 | 3.28e-01 | 0.2326 |
| 54801 | HAUS6 | SYSMH3 | Human | Oral cavity | OSCC | 3.96e-20 | 5.33e-01 | 0.2442 |
| 54801 | HAUS6 | SYSMH6 | Human | Oral cavity | OSCC | 5.11e-05 | 2.38e-01 | 0.1275 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00070517 | Oral cavity | OSCC | spindle organization | 117/7305 | 184/18723 | 1.16e-11 | 4.17e-10 | 117 |
| GO:00512255 | Oral cavity | OSCC | spindle assembly | 73/7305 | 117/18723 | 2.51e-07 | 3.96e-06 | 73 |
| GO:00070981 | Oral cavity | OSCC | centrosome cycle | 66/7305 | 130/18723 | 4.17e-03 | 1.70e-02 | 66 |
| GO:00310232 | Oral cavity | OSCC | microtubule organizing center organization | 70/7305 | 143/18723 | 9.71e-03 | 3.44e-02 | 70 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| HAUS6 | SNV | Missense_Mutation | c.799N>G | p.Leu267Val | p.L267V | Q7Z4H7 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| HAUS6 | SNV | Missense_Mutation | rs761923103 | c.979N>G | p.Gln327Glu | p.Q327E | Q7Z4H7 | protein_coding | tolerated(0.15) | benign(0.009) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| HAUS6 | SNV | Missense_Mutation | c.222N>G | p.Phe74Leu | p.F74L | Q7Z4H7 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| HAUS6 | SNV | Missense_Mutation | novel | c.1764G>C | p.Leu588Phe | p.L588F | Q7Z4H7 | protein_coding | tolerated(0.05) | possibly_damaging(0.683) | TCGA-AC-A3W6-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| HAUS6 | SNV | Missense_Mutation | novel | c.173N>A | p.Ser58Tyr | p.S58Y | Q7Z4H7 | protein_coding | deleterious(0.01) | possibly_damaging(0.668) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| HAUS6 | SNV | Missense_Mutation | c.2426G>A | p.Gly809Asp | p.G809D | Q7Z4H7 | protein_coding | tolerated(0.48) | benign(0.009) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| HAUS6 | SNV | Missense_Mutation | rs746342417 | c.1744C>T | p.Pro582Ser | p.P582S | Q7Z4H7 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD |
| HAUS6 | SNV | Missense_Mutation | c.1649C>G | p.Ser550Cys | p.S550C | Q7Z4H7 | protein_coding | deleterious(0) | probably_damaging(0.98) | TCGA-B6-A0RT-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| HAUS6 | SNV | Missense_Mutation | c.1144N>A | p.Glu382Lys | p.E382K | Q7Z4H7 | protein_coding | tolerated(0.49) | benign(0.019) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| HAUS6 | SNV | Missense_Mutation | novel | c.1753N>T | p.Pro585Ser | p.P585S | Q7Z4H7 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |